https://www.benzinga.com/insights/earnings/24/03/37422651/a-preview-of-avadel-pharmaceuticalss-earnings
A Preview Of Avadel Pharmaceuticals's Earnings - Benzinga
a previewavadel pharmaceuticalsearningsbenzinga
https://www.biospace.com/press-releases/avadel-pharmaceuticals-expands-leadership-team-with-appointment-of-susan-rodriguez-as-chief-operating-officer
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief...
avadel pharmaceuticalsleadership team
https://www.benzinga.com/news/earnings/22/05/27070602/recap-avadel-pharmaceuticals-q1-earnings
Recap: Avadel Pharmaceuticals Q1 Earnings - Benzinga
May 9, 2022 - Avadel Pharmaceuticals (NASDAQ:AVDL) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the...
avadel pharmaceuticalsrecapq1earningsbenzinga
https://www.biospace.com/press-releases/avadel-pharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference
Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - BioSpace
avadel pharmaceuticalsglobal healthcarepresent
https://www.fool.com/earnings/call-transcripts/2020/03/12/avadel-pharmaceuticals-plc-avdl-q4-2019-earnings-c.aspx
Avadel Pharmaceuticals plc (AVDL) Q4 2019 Earnings Call Transcript | The Motley Fool
Mar 12, 2020 - AVDL earnings call for the period ending December 31, 2019.
earnings call transcriptavadel pharmaceuticalsq4 2019
https://www.biospace.com/avadel-pharmaceuticals-announces-publication-in-clinical-therapeutics-of-data-highlighting-weight-loss-in-people-with-narcolepsy-treated-with-lumryz-sodium-oxybate-extended-release-oral-suspension
Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight...
avadel pharmaceuticalsclinical therapeuticsannouncespublication
https://www.financialcontent.com/quote/NQ:AVDL
Avadel Pharmaceuticals plc - Ordinary Share (AVDL) Stock Price, News, Quote & History |...
The current price of Avadel Pharmaceuticals plc - Ordinary Share (AVDL) is 21.64. Avadel Pharmaceuticals is a biopharmaceutical company focused on developing...
avadel pharmaceuticalsordinary sharestock priceplc
https://www.biospace.com/avadel-pharmaceuticals-to-report-third-quarter-2019-financial-results-on-november-12th
Avadel Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12th - BioSpace
Oct 29, 2019 - Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating...
2019 financial results
https://www.biospace.com/avadel-pharmaceuticals-announces-submission-of-new-drug-application-for-ft218-to-the-fda
Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA - BioSpace
Dec 16, 2020 - Avadel Pharmaceuticals plc (Nasdaq: AVDL) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for...
https://www.biospace.com/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2024-financial-results-on-august-8
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2024 Financial...
https://www.biospace.com/avadel-pharmaceuticals-reports-third-quarter-2020-financial-results-and-provides-update-on-ft218-development-program
Avadel Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Update on FT218...
Nov 10, 2020 - New market assessment dataidentifies a significant potential market expansion opportunity for once-nightly FT218beyondexisting twice-nightly sodium oxybate...